HOPE Therapeutics, NRx Pharmaceuticals cleared to close Dura Medical acquisition

HOPE Therapeutics, a wholly-owned subsidiary of NRx Pharmaceuticals (NRXP), announced it has received final clearance and approval from the Florida Agency for Health Care Administration to proceed closing of the Dura Medical acquisition, in connection with its change of ownership applications, a key regulatory step for closing. Dura is revenue generating and EBITDA positive. The acquisition is expected to be accretive to revenue and EBITDA.